Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this observational study is to describe the natural course of vascular Ehlers-Danlos syndrome, in particular the order of appearance of different types of complications (arterial, digestive, pulmonary and uterine).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Description of the natural course of vascular Ehlers-Danlos syndrome (vEDS) based on anatomical criteria (number and type of arterial lesions or angioscanner or MRI) | Through study completion, an average of 3 years | |
| Description of the natural course of vascular Ehlers-Danlos syndrome (vEDS) based on functional criteria (spontaneous arterial, digestive, obstetrical and pulmonary events) | Through study completion, an average of 3 years | |
| Description of the natural course of vascular Ehlers-Danlos syndrome (vEDS) based on surgical criteria (types and complications) | Through study completion, an average of 3 years | |
| Description of the natural course of vascular Ehlers-Danlos syndrome (vEDS) based on evaluation of the quality of life (impact on daily life, social life and professional activity) | Through study completion, an average of 3 years | |
| Description of the natural course of vascular Ehlers-Danlos syndrome (vEDS) based on evaluation of mortality (death, disability) | Through study completion, an average of 3 years | |
| Description of the natural course of vascular Ehlers-Danlos syndrome (vEDS) based on the presence of complications at delivery or after C-section | Through study completion, an average of 3 years |
| Measure | Description | Time Frame |
|---|---|---|
| Study of prospective genotype-phenotype relationships | Mutations of the COL3A1 gene are stratified within 5 classes (Frank et al. Eur J Hum Genet 2015):
An association study between the type of mutation in the COL3A1 gene (individually or combined in two groups: (a+b) versus (c+d+e)) and the clinical phenotype or co-factors of morbidity (medication, lifestyle, smoking, physical activity…) will be performed. This study will be based on explicative multivariate analysis (e.g.: PCA, Logistic regression, ect.) and relevant association will be quantified by the corresponding correlation coefficient. |
Not provided
Inclusion Criteria:
Patients eligible for inclusion in this study have to fulfil all of the following criteria:
There are no exclusion criteria for this study.
Not provided
Not provided
Not provided
Not provided
Patients diagnosed as vEDS on a positive genetic testing on the COL3A1 gene.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Xavier JEUNEMAITRE | INSERM UMR S970 | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre Hospitalier Universitaire Angers | Angers | France | ||||
| Hôpital Saint-André |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000094623 | Ehlers-Danlos Syndrome, Type IV |
| ID | Term |
|---|---|
| D000784 | Aortic Dissection |
| D000094665 | Dissection, Blood Vessel |
| D000783 | Aneurysm |
| D014652 | Vascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Through study completion, an average of 3 years |
| Study of the intrafamilial phenotypes relationships | This study will be based on an explicative multivariate analysis (eg: PCA, Logistic regression, ect.) and relevant associations will be quantified by the corresponding correlation coefficients. Distribution of clinical symptoms with a positive correlation with the family history, will be displayed and illustrated by appropriate graphic method (Bar chart, box plot, forest plot, etc.). | Through study completion, an average of 3 years |
| Evaluation of the global cost of vEDS cares | The analysis of the global cost of vEDS cares will be detailed by type of expenditure. The average cost will be estimated with health-care payer's perspective, i.e. the French health insurance system. After estimating the average global cost of vEDS cares, including both standard pathway's cost and vEDS' cost, a Tornado diagram will analyse the impact of the change of one or more parameters used in the analysis process. This will allow us to identify which parameters have an impact on the result by introducing uncertainties on values used. These parameters will vary in a range obtained by literature review, expert opinion or arbitrarily by simulation on a normal distribution. All the results will be drafted in statistical medico-economic analysis report to be presented to all investigators at the end of the study. | Through study completion, an average of 3 years |
| Evaluation of the therapeutic management | A descriptive analysis of the different types of medication (celiprolol alone or associated to another drug) and their association to disease progression and life style will be performed by evaluating the number of lesions and/or the increased severity of the lesions and/or the appearance of lesions at different anatomical site. | Through study completion, an average of 3 years |
| Assessment of the correlation between the diffusion of arterial lesions and the occurrence of cardiovascular complication | Through study completion, an average of 3 years |
| Assessment of the repercussions of vEDS on patients' quality of life evaluated through scores of quality of life questionnaire Short-Form Health Survey (SF-36) | Through study completion, an average of 3 years |
| Assessment of the repercussions of vEDS on patients' quality of life evaluated through scores of quality of life questionnaire Short-Form Health Survey (SF-10) | Through study completion, an average of 3 years |
| Assessment of the repercussions of vEDS on patients' quality of life evaluated through scores of quality of life questionnaire HADS | Through study completion, an average of 3 years |
| Assessment of the repercussions of vEDS on patients' quality of life evaluated through scores of quality of life questionnaire socio-professional life | Through study completion, an average of 3 years |
| Bordeaux |
| France |
| Hôpital de la Cavale Blanche | Brest | France |
| Hôpital Côte de Nacre | Caen | France |
| Hôpital Gabriel Montpied | Clermont-Ferrand | France |
| Hôpital Michallon | Grenoble | France |
| Hôpital Claude Huriez | Lille | France |
| Hôpital Edouard Herriot | Lyon | France |
| Hôpital Femme Mère Enfant | Lyon | France |
| Hôpital de la Timone | Marseille | France |
| Hôpital Saint-Eloi | Montpellier | France |
| Hôpital Brabois | Nancy | France |
| Hôpital Hôtel Dieu | Nantes | France |
| Hôpital Européen Georges Pompidou | Paris | France |
| Hôpital Nord | Saint-Etienne | France |
| Hôpital Rangueil | Toulouse | France |
| Hôpital Trousseau | Tours | France |
| D002318 |
| Cardiovascular Diseases |
| D004535 | Ehlers-Danlos Syndrome |
| D020141 | Hemostatic Disorders |
| D006474 | Hemorrhagic Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D012868 | Skin Abnormalities |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D012873 | Skin Diseases, Genetic |
| D030342 | Genetic Diseases, Inborn |
| D003095 | Collagen Diseases |
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D012871 | Skin Diseases |